ST5589 hydrochloride | 1232885-04-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ST5589 hydrochloride
• 英文别名: 4-(morpholin-4-yl)butyric acid 3-adamantan-1-yl-4'-((E)-2-carboxyvinyl)biphenyl-4-yl ester hydrochloride；(E)-3-[4-[3-(1-adamantyl)-4-(4-morpholin-4-ylbutanoyloxy)phenyl]phenyl]prop-2-enoic acid;hydrochloride
• CAS: 1232885-04-9
• 化学式: C₃₃H₃₉NO₅*ClH
• 分子量: 566.137
• InChiKey: YIMZSIFKBNRPNY-OAZHBLANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.36
• 重原子数：
  40
• 可旋转键数：
  10
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  76.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ST5589 hydrochloride 在 水 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 以12%的产率得到阿达罗汀
  参考文献：
  名称：

  New retinoid derivatives as back-ups of Adarotene

  摘要：

  Adarotene belongs to the so-called class of atypical retinoids. The presence of the phenolic hydroxyl group on Adarotene structure allows a rapid O-glucuronidation as a major mechanism of elimination of the drug, favoring a fast excretion of its glucuronide metabolite in the urines. A series of ether, carbamate and ester derivatives was synthesized. All of them were studied and evaluated for their stability at different pH. The cytotoxic activity in vitro on NCI-H460 non-small cell lung carcinoma and A2780 ovarian tumor cell lines was also tested. A potential back-up of Adarotene has been selected to be evaluated in tumor models. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.042
• 作为产物：
  描述：

  3-(金刚烷-1-基)-4'-溴-[1,1'-联苯]-4-醇 在 盐酸 、 palladium diacetate 、 三乙胺 、 N,N-二异丙基乙胺 、 三(邻甲基苯基)磷 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 ST5589 hydrochloride
  参考文献：
  名称：

  New retinoid derivatives as back-ups of Adarotene

  摘要：

  Adarotene belongs to the so-called class of atypical retinoids. The presence of the phenolic hydroxyl group on Adarotene structure allows a rapid O-glucuronidation as a major mechanism of elimination of the drug, favoring a fast excretion of its glucuronide metabolite in the urines. A series of ether, carbamate and ester derivatives was synthesized. All of them were studied and evaluated for their stability at different pH. The cytotoxic activity in vitro on NCI-H460 non-small cell lung carcinoma and A2780 ovarian tumor cell lines was also tested. A potential back-up of Adarotene has been selected to be evaluated in tumor models. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.042

文献信息

• RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES
  申请人：Cabri Walter

  公开号：US20110312965A1

  公开（公告）日：2011-12-22

  The present invention relates to new retinoid derivatives of formula I and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumours, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.

  本发明涉及公式I的新视黄醇衍生物和含有这些衍生物的药物组合物，用于治疗患有关节炎、肿瘤、转移性癌症、糖尿病性视网膜病变、银屑病、慢性炎症性疾病或动脉粥样硬化等病理的患者。
• USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN
  申请人：Fabius Biotechnology

  公开号：US20210338558A1

  公开（公告）日：2021-11-04

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.
• US8530517B2
  申请人：——

  公开号：US8530517B2

  公开（公告）日：2013-09-10
• [EN] USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN<br/>[FR] UTILISATION DE DOMAINES DE LIAISON AU COLLAGÈNE POUR DÉLIVRER DES PRODUITS À LA PEAU
  申请人：FABIUS BIOTECHNOLOGY

  公开号：WO2020068665A1

  公开（公告）日：2020-04-02

  The present invention addresses the need for an improved delivery system that is able to specifically target the skin for improved bioavailability and minimization of side effects resulting from administration of the active ingredient or ingredients. One aspect of the present invention is a targeting composition comprising: (1 ) a skin care agent or an agent that is a cosmeceutical agent; (2) an intermediate release linker bound to the skin care agent or cosmeceutical agent; (3) a targeting moiety bound to the intermediate release linker, the targeting moiety for binding the targeting composition to native collagen fibers; and (4) optionally, a carrier component to enhance delivery to the skin. The present invention also describes methods of use of these targeting compositions.